Patents Assigned to JUVENTAS THERAPEUTICS, INC.
-
Patent number: 9844581Abstract: A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification.Type: GrantFiled: December 9, 2013Date of Patent: December 19, 2017Assignees: The Cleveland Clinic, Juventas Therapeutics, Inc.Inventors: Marc S. Penn, Rahul Aras, Joseph Pastore, Timothy J. Miller
-
Publication number: 20170049856Abstract: Provided herein are methods of treating a cardiomyopathy in a subject by administering directly to, or expressing locally in, a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification. Methods of treating subjects with advanced ischemic cardiomyopathy are further disclosed herein.Type: ApplicationFiled: April 28, 2015Publication date: February 23, 2017Applicants: Juventas Therapeutics, Inc., The Cleveland Clinic FoundationInventors: Marc S. PENN, Rahul ARAS, Joseph PASTORE, Timothy J. MILLER
-
Patent number: 8883756Abstract: Provided herein are methods of treating a cardiomyopathy in a subject by administering directly to, or expressing locally in, a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification. Also provided are methods of treating critical limb ischemia in a subject by administering a DNA plasmid encoding human SDF-1 by direct injection into the affected limb.Type: GrantFiled: June 7, 2013Date of Patent: November 11, 2014Assignee: Juventas Therapeutics, Inc.Inventors: Marc S. Penn, Rahul Aras, Joseph Pastore, Timothy J. Miller
-
Publication number: 20140186419Abstract: The subject matter provided herein relates to method for inhibiting or mitigating scar formation in a wound of the skin, by increasing the concentration of SDF-1 in, or proximate to, the wound. As described herein SDF-1 protein or an SDF-1 expression vector can be administered to a wound or the area proximate a wound by providing a therapeutically effective amount of SDF-1 protein or an SDF-1 expression vector.Type: ApplicationFiled: February 7, 2014Publication date: July 3, 2014Applicants: Juventas Therapeutics, Inc., The Cleveland Clinic FoundationInventors: Marc S. Penn, Matthew Kiedrowski, Rahul Aras, Joseph Pastore
-
Publication number: 20140135383Abstract: A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification.Type: ApplicationFiled: December 9, 2013Publication date: May 15, 2014Applicants: Juventas Therapeutics, Inc., The Cleveland Clinic FoundationInventors: Marc S. Penn, Rahul Aras, Joseph Pastore, Timothy J. Miller
-
Patent number: 8679477Abstract: The subject matter provided herein relates to method for inhibiting or mitigating scar formation in a wound of the skin, by increasing the concentration of SDF-1 in, or proximate to, the wound. As described herein SDF-1 protein or an SDF-1 expression vector can be administered to a wound or the area proximate a wound by providing a therapeutically effective amount of SDF-1 protein or an SDF-1 expression vector.Type: GrantFiled: October 12, 2012Date of Patent: March 25, 2014Assignees: The Cleveland Clinic Foundation, Juventas Therapeutics, Inc.Inventors: Marc S. Penn, Matthew Kiedrowski, Rahul Aras, Joseph Pastore
-
Patent number: 8513007Abstract: A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification.Type: GrantFiled: July 24, 2012Date of Patent: August 20, 2013Assignees: The Cleveland Clinic Foundation, Juventas Therapeutics, Inc.Inventors: Marc S. Penn, Rahul Aras, Joseph Pastore, Timothy J. Miller
-
Patent number: 8513213Abstract: A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification.Type: GrantFiled: July 24, 2012Date of Patent: August 20, 2013Assignees: The Cleveland Clinic Foundation, Juventas Therapeutics, Inc.Inventors: Marc S. Penn, Rahul Aras, Joseph Pastore, Timothy J. Miller
-
Publication number: 20130034523Abstract: The subject matter provided herein relates to method for inhibiting or mitigating scar formation in a wound of the skin, by increasing the concentration of SDF-1 in, or proximate to, the wound. As described herein SDF-1 protein or an SDF-1 expression vector can be administered to a wound or the area proximate a wound by providing a therapeutically effective amount of SDF-1 protein or an SDF-1 expression vector.Type: ApplicationFiled: October 12, 2012Publication date: February 7, 2013Applicants: JUVENTAS THERAPEUTICS, INC., THE CLEVELAND CLINIC FOUNDATIONInventors: The Cleveland Clinic Foundation, Juventas Therapeutics, Inc.